Targeting epigenetics for the treatment of prostate cancer: recent progress and future directions.

Authors

• Jianqing Lin
• Chenguang Wang
• Wm Kevin Kelly

Publication/Presentation Date

6-1-2013

Abstract

Epigenetic aberrations contribute to prostate cancer carcinogenesis and disease progression. Efforts have been made to target DNA methyltransferase and histone deacetylases (HDACs) in prostate cancer and other solid tumors but have not had the success that was seen in the hematologic malignancies. Oral, less toxic, and more specific agents are being developed in solid tumors including prostate cancer. Combinations of epigenetic agents alone or with a targeted agent such as androgen receptor signaling inhibitors are promising approaches and will be discussed further.

Volume

40

Issue

3

First Page

393

Last Page

401

ISSN

1532-8708

Published In/Presented At

Lin, J., Wang, C., & Kelly, W. K. (2013). Targeting epigenetics for the treatment of prostate cancer: recent progress and future directions. Seminars in oncology, 40(3), 393–401. https://doi.org/10.1053/j.seminoncol.2013.04.010

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

23806502

Department(s)

Administration and Leadership

Document Type

Article